Study of PXL01 Versus Placebo to Inhibit Adhesion Formation After Flexor Tendon Surgery (PHSU02)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01022242|
Recruitment Status : Completed
First Posted : December 1, 2009
Results First Posted : May 29, 2014
Last Update Posted : May 29, 2014
|Condition or disease||Intervention/treatment||Phase|
|Surgical Adhesions||Drug: PXL01 Drug: Placebo||Phase 2|
This is a multi-centre, randomized, double blind, parallel study design in patient admitted for flexor tendon repair in zone II.
The patients will undergo 9 visits within the time frame of the study. Patients will be randomized to receive treatment with PXL01 or standard care.
Primary objective is to assess total active motion based on PIP and DIP joints (TAM2) at 12-week visit. Secondary objectives are to assess TAM2 at all time points except for 12 weeks, TAM based on MCP, PIP, and DIP joints (TAM3) at all time points, Total Active Motion in DIP joint (DIPAM), tip-to-crease, grip strength and Total Passive Motion (TPM2 and TPM3).
Before any study-related assessment takes place, patients are given verbal and written information about the study and informed consent is achieved from the patient and/or legal guardian. The study should be carried out in accordance with the Clinical Study Protocol (CSP), ICH guidelines for Good Clinical Practise (GCP), and applicable regulatory requirements.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||138 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Double (Participant, Outcomes Assessor)|
|Official Title:||A Prospective Double-blind, Randomised Concept Study of PXL01 Versus Placebo in Flexor Tendon Surgery|
|Study Start Date :||December 2009|
|Actual Primary Completion Date :||May 2012|
|Actual Study Completion Date :||February 2013|
Placebo Comparator: Placebo
Placebo is administered locally between the flexor tendon and the tendon sheath and around the tendon sheath at a volume of 0.5 ml. Administration of the product is carried out after repair of the flexor tendon but before closure of the surgical wound.
Placebo is a physiological sodium chloride solution, which is clear and colourless.
PXL01 is administered locally between the flexor tendon and the tendon sheath and around the tendon sheath at a volume of 0.5 ml. Administration of the product is carried out after repair of the flexor tendon but before closure of the surgical wound.
PXL01 is a synthetic peptide sequentially derived from human lactoferrin. PXL01 is formulated in a viscous solution of sodium hyaluronate. The drug product is administered locally between the flexor tendon and the tendon sheath and around the tendon sheath at a volume of 0.5 ml. Administration of the product is carried out after repair of the flexor tendon but before closure of the surgical wound.
- TAM2 [ Time Frame: At 12 weeks after surgery ]The primary variable is TAM2: The sum of Total Active Motion at the proximal interphalangeal (PIP) and distal interphalangeal (DIP) joints of the affected digit at actively made fist minus the extensor lag at these joints.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01022242
|Dept. of Hand Surgery, Aalborg Hospital|
|Aalborg, Denmark, 9000|
|Dept. of Hand Surgery, Odense University Hospital|
|Odense, Denmark, 5000|
|Klinik für Handchirurgie der Herz- und Gefäß-Klinik GmbH|
|Bad Neustadt, Germany, 97616|
|Katholisches Klinikum Duisburg, St. Barbara Hospital, Klinik für Plastische Chirurgie und Handchirurgie|
|Duisburg, Germany, 47166|
|St.Josef Hospital Essen- Kupferdreh, Abteilung für Handchirurgie|
|Essen, Germany, 45257|
|Klinik für Plastische, Hand- und Wiederherstellungschirurgie, Medizinische Hochschule Hannover|
|Hannover, Germany, 30625|
|Universitätsklinikum des Saarlandes, Klinik für Unfall-, Hand - und Wiederherstellungschirugie|
|Homburg, Germany, 66421|
|Universitätsklinikum Schleswig-Holstein, Campus Lübeck, Sektion für Plastische Chirurgie, Handchirurgie und Intensiveinheit für Schwerbrandverletzte|
|Lübeck, Germany, 23538|
|Ludwig-Maximilians Universität München, Klinik und Poliklinik für Plastische Chirurgie und Handchirurgie, Campus Innenstadt|
|Munich, Germany, 80336|
|Ludwig-Maximilians Universität München, Klinik und Poliklinik für Plastische Chirurgie und Handchirurgie, Campus Großhadern|
|Munich, Germany, 81377|
|Klinik für Handchirurgie, Mikrochirurgie und Rekonstruktive Brustchirurgie Vinzenz von Paul Kliniken GmbH|
|Stuttgart, Germany, 70199|
|Dept. of Hand Surgery Sahlgrenska University Hospital|
|Gothenburg, Sweden, SE-413 45|
|Dept. of Hand Surgery Malmö University Hospital|
|Malmö, Sweden, SE-20502|
|Dept. of Hand Surgery, Stockholm South General Hospital|
|Stockholm, Sweden, 118 83|
|Dept. of Hand Surgery Uppsala University Hospital, entrance 70|
|Uppsala, Sweden, SE-75185|
|Principal Investigator:||Monica Wiig, MD, PhD||Dept. of Hand Surgery Uppsala University Hospital|